Ascentage Pharma director updates equity holdings

ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an amended initial ownership report that corrects and clarifies his equity holdings.

Accepted by SEC EDGAR 03/23/2026 - 07:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an amended initial ownership report that corrects and clarifies his equity holdings. The filing shows options over 18,850 Ordinary Shares at an exercise price of $8.14 expiring on November 26, 2035, 28,850 restricted share units that vest in four equal annual installments from November 26, 2026 through 2029, and 8,964 Ordinary Shares held directly. Footnotes explain that the numbers of Ordinary Shares, share options, and vesting schedules were inadvertently reported incorrectly in the original submission.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Ye Changqing

Role Director

Type	Security	Shares	Price	Value
Holding	Options	--	--	--
Holding	Restricted share units	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Options — 18,850 contracts (Direct); Restricted share units — 28,850 contracts (Direct); Ordinary Shares — 8,964 shares (Direct)

Footnotes (5)

1. F1. The number of Ordinary Shares were inadvertently not reported in the original submission.
2. F2. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.
3. F3. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
4. F4. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
5. F5. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ye Changqing

(Last) (First) (Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	8,964(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(2)	11/26/2035	Ordinary Shares	18,850(5)	$8.14(3)	D
Restricted share units	(4)	(4)	Ordinary Shares	28,850	$0	D

Explanation of Responses:

1. The number of Ordinary Shares were inadvertently not reported in the original submission.

2. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.

3. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

4. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

5. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

Remarks:

	/Chnagqing Ye/	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)